At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Jun 24, 2026 at 22:33 ET
Taysha Gene Therapies announced the pricing of a $200M underwritten public offering of 32.5M shares at $6.00/share, plus pre-funded warrants. The offering represents significant dilution (~30% of pre-offer shares based on market cap) for a clinical-stage biotech with no approved products. Proceeds will fund operations and pipeline development, but the dilutive structure is a clear negative signal for existing shareholders.
- Offering of 32,500,001 shares at $6.00/share plus pre-funded warrants for 833,333 shares
- Gross proceeds expected to be ~$200.0 million before underwriting discounts and commissions
- Underwriters granted 30-day option to purchase up to 5,000,000 additional shares
- Offering expected to close on or about June 26, 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access